Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine Citrate Effects on VAP-1 in Healthy Volunteers
NCT02098785Phase 1Withdrawn
- Sponsor
- University of Birmingham
- Start
- Mar 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of caffeine in liver disease, sponsored by University of Birmingham. Primary endpoint: Vascular Adhesion Protein-1 serum levels. Planned start Mar 2018; status: withdrawn.
02
Drugs
caffeine
03
Conditions
liver disease
Beyond the preview
Go deeper on NCT02098785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098785.